A retrospective outpatient study linked Passiflora extract and cognitive behavioral therapy with greater dose reduction. Treatment selection and a coarse therapy measure limit causal interpretation.
The study included 186 patients in clinical remission undergoing benzodiazepine tapering. Ninety-three received a dry extract and ninety-three matched controls followed a standard tapering approach. Therapy participation was recorded as a binary chart variable.
At three months, both extract use and therapy were associated with larger reductions in diazepam-equivalent dose. The model also reported an interaction between them.
A statistical interaction in an observational model does not prove a biological synergistic mechanism. Clinician choice, patient preference, motivation, and other treatment differences can affect both allocation and dose reduction. Therapy intensity and fidelity were not fully represented by a yes/no measure.
Adherence was based on patient or caregiver accounts. Three-month reduction is also different from complete sustained discontinuation, absence of withdrawal, or long-term recovery.
Present the findings as associations with a specific extract and care setting. The paper cannot establish that any passionflower product safely accelerates tapering or that adding the product would have prevented an individual withdrawal complication.
Original analysis of the supplied journal article, identified as PMC12845437.